6667 — Mega Genomics Cashflow Statement
0.000.00%
Last trade - 00:00- HK$2.34bn
- HK$1.83bn
- CNY151.30m
- 89
- 16
- 70
- 64
Annual cashflow statement for Mega Genomics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 38.3 | 94.9 | 95.9 | -21.4 | 36.2 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 25.4 | 14.8 | 9.72 | 15.2 | -10.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -40.5 | -20.9 | -88.9 | -15.9 | 123 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 37.3 | 103 | 30.6 | -6.91 | 164 |
| Capital Expenditures | -0.761 | -1.04 | -4.42 | -5.19 | -36.1 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 18.4 | -30 | 2.71 | 2.63 | 2.34 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 17.7 | -31.1 | -1.71 | -2.56 | -33.8 |
| Financing Cash Flow Items | -3.05 | 98.1 | -216 | -18.4 | 6.94 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -20.3 | 84.1 | 2.62 | 158 | -12.9 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 34.7 | 156 | 30.6 | 161 | 118 |